ClinicalTrials.gg
WithdrawnNCT06411639Updated Jan 27, 2025

Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases

A Phase 1 interventional study of ianalumab in Sjogren Disease and Systemic Lupus Erythematosus, sponsored by Novartis Pharmaceuticals. Withdrawn. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Strategic decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Lupus Erythematosus, Systemic by Novartis — 2 open to participants now, 8 under way, 4 of them phase 3. Lupus Erythematosus, Systemic · Novartis.

Enrollment
14th of 14
0 · median 131
Started
2024
with 4 others
Phase 1
4 of 14
1 open now
Registered
12th of 14
by date

Among the 14 studies in Lupus Erythematosus, Systemic by Novartis, this one is the 14th largest by enrollment, is one of 5 that started in 2024, is one of 4 in phase 1, and was the 12th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

2 of the 14 studies in Lupus Erythematosus, Systemic by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Lupus Erythematosus, Systemic by Novartis, or all of them as a file.
02

Study summary

The purpose of this pharmacokinetic (PK) study is to describe the PK profile of ianalumab following s.c. administration in Chinese participants with systemic lupus erythematosus (SLE) and/or Sjögren's disease (SjD). Collection of intensive PK data from Chinese population had been designed in the ianalumab Phase 3 studies of SjD CVAY736A2302 (NCT05349214) and lupus nephritis (LN) CVAY736K12301 (NCT05126277) on an optional basis. This study is conducted to provide supplementary Chinese PK data in addition to the intensive PK data from the two Phase 3 studies .

Read the detailed description

The study consists of the following periods:

  • Screening Period: up to 4 weeks
  • Treatment Period (Week 0 - Week 12) : 12 weeks
  • Extended Treatment Period (after the completion of Week 12 - Week 52 (End of Treatment (EoT)) : 40 weeks

    \~ After completion of the 12-week treatment, participants will have the option to enter the Extended Treatment Period. If a participant does not enter the Extended Treatment Period, the EoT visit will be performed at the next planned visit following the completion of Week 12, followed by the Post-treatment Follow-up Period.

  • Post-treatment Follow-up Period: at least 20 weeks and up to 2 years from the last dose of study treatment.
03

Conditions studied

  • Sjogren Disease
  • Systemic Lupus Erythematosus

Keywords

  • Pharmacokinetic (PK)
  • Systemic lupus erythematosus (SLE)
  • Sjogren Disease (SjD)
  • VAY736
  • ianalumab
  • B cell depletion
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male and female patients 18 years to 70 years of age (inclusive)
  • Body weight at least 35 kg and not more than 120 kg and must have a (BMI) within the range of 18 - 35 kg/m2. BMI = Body weight (kg) / [Height (m)]2 at screening
  • Diagnosed with SjD and/or SLE as determined by the investigator
  • Have active disease (SjD and/or SLE) that may benefit from B-cell depletion therapy, as determined by the investigator.
  • Participants currently receiving protocol-allowed SoC should be on stable doses of SoC medications for 4 weeks prior to first dosing of study treatment

Key Exclusion Criteria:

  • Use of prohibited therapies
  • Active viral, bacterial or other infections requiring systemic treatment at the time of screening or baseline or history of recurrent infection
  • Receipt of live/attenuated vaccine within a 4-week period before first dosing
  • Uncontrolled co-existing serious disease
  • Pregnant or nursing (lactating) women
  • Women of (WOCBP), defined as all women physiologically capable of becoming pregnant, refusing or unable to use highly effective methods of while on study treatment and for 6 months after stopping of study drug

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Ianalumab 300 mg

    Participants will receive Ianalumab 300 mg subcutaneous (s.c.) monthly

    Drug: ianalumab

Interventions

  • ianalumab will be provided in a pre-filled Syringe (PFS) of 150 mg/1 mL for s.c. administration. Two injections of 1mL each will be administered monthly.

    Also known as: VAY736

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) calculated to the end of a dosing interval (tau) at steady-state (AUCtau) of ianalumab after the 3rd dose

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of ianalumab. AUCtau of ianalumab will be summarized with descriptive statistics.

    Time frame: Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)

  2. Observed maximum blood concentration (Cmax)of ianalumab after the 3rd dose

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of ianalumab. Cmax of ianalumab will be summarized with descriptive statistics.

    Time frame: Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)

  3. Time of maximum observed drug concentration occurrence (Tmax) of ianalumab after the 3rd dose

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of ianalumab. Tmax of ianalumab will be summarized with descriptive statistics.

    Time frame: Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)

Secondary outcomes

  1. Ctrough of ianalumab at the end of dosing interval

    Venous whole blood samples will be collected for activity-based pharmacokinetics characterization of ianalumab. Ctrough of ianalumab will be summarized with descriptive statistics.

    Time frame: Week 8 to 12 (Day 57): Pre-dose, Post-dose (24 hours (hr) +/- 12hr, 72 hr +/- 24 hr, 168 hr +/- 72 hr, 336 hr +/- 72hr, 504 hr +/- 72hr)

  2. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters.

    Time frame: From date of enrollment till 30 days after end of Treatment, assessed up to approximately 44 months

  3. Anti-ianalumab antibodies (ADA)

    Immunogenicity (IG) blood samples will be collected for anti-drug antibodies characterization. ADA of ianalumab will be summarized with descriptive statistics.

    Time frame: Day 1 (Baseline), Week 8 to 11 Day 57 (Pre-dose), Week 12 Day 85, Week 24 Day 169, Week 36 Day 253, Week 52 Day 365, Week 68 Day 477 and Week 156 Day 1093

  4. Presence of anti-drug antibodies (ADA)

    Immunogenicity (IG) blood samples will be collected to assess the presence ADA of ianalumab.

    Time frame: Day 1 (Baseline), Week 8 to 11 Day 57 (Pre-dose), Week 12 Day 85, Week 24 Day 169, Week 36 Day 253, Week 52 Day 365, Week 68 Day 477 and Week 156 Day 1093

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2024; primary completion for Dec 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2024
First posted
May 13, 2024
StartEst.
Nov 25, 2024
Primary completionEst.
Dec 17, 2025
CompletionEst.
Jun 24, 2028
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06411639
Responsible party
Sponsor
First posted
May 13, 2024
Start date
Nov 25, 2024 (estimated)
Primary completion
Dec 17, 2025 (estimated)
Completion
Jun 24, 2028 (estimated)
Last update
Jan 27, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion